Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prochlorperazine
Drug ID BADD_D01848
Description Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management of psychotic disorders such as generalized non-psychotic anxiety and schizophrenia.[label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.[L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956. Although newer antiemetic agents such as 5-HT3 antagonists are more heavily promoted, prochlorperazine is still widely used in nausea and vomiting.[L6640]
Indications and Usage For the symptomatic management of psychotic disorders, short term management of nonpsychotic anxiety in patients with generalized anxiety disorder, and for the control of severe nausea and vomiting of various causes.
Marketing Status Prescription; Discontinued
ATC Code N05AB04
DrugBank ID DB00433
KEGG ID D00493
MeSH ID D011346
PubChem ID 4917
TTD Drug ID D0B2UZ
NDC Product Code 69575-4017; 0713-0135; 54348-114; 63629-8444; 55289-119; 54348-989; 46204-0007; 50090-0636; 0574-7226
Synonyms Prochlorperazine | Prochlorperazine Edisylate Salt | Edisylate Salt, Prochlorperazine | Salt, Prochlorperazine Edisylate | Prochlorperazine Edisylate | Edisylate, Prochlorperazine | Prochlorperazine Maleate | Maleate, Prochlorperazine | Compazine
Chemical Information
Molecular Formula C20H24ClN3S
CAS Registry Number 58-38-8
SMILES CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Metabolic disorderGlucose-6-phosphatase catalytic subunit 1P35575Not Available2833274; 2106830; 2116902
Metabolic disorderUDP-glucuronosyltransferase 1A1P22309T934802833274; 2106830; 2116902
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperpyrexia08.05.02.002--Not Available
Hyperreflexia17.02.01.002--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.001046%
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypotension24.06.03.002--
Hypoxia22.02.02.0030.001046%
Ileus paralytic07.02.05.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Influenza11.05.03.001; 22.07.02.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Keratopathy06.06.03.007--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Laryngospasm22.04.02.002--
Lenticular opacities06.06.01.003--Not Available
Leukopenia01.02.02.001--Not Available
Malaise08.01.01.0030.001046%
Masked facies17.01.05.007--Not Available
Megacolon07.02.05.002--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Miosis17.02.11.002; 06.05.03.003--Not Available
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle spasms15.05.03.0040.000273%
Mydriasis06.05.03.004; 17.02.11.003--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.0010.003660%
Nervousness19.06.02.003--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages